January 2026

FDA QMSR Alignment to ISO 13485: Key Changes Ahead

While the industry has been anticipating alignment with ISO 13485 for years, the final rule brings both clarity and new expectations that every device manufacturer must understand.

Caitlin Kinard, Senior Quality Specialist

SYNOPSIS

As a quality team supporting biopharmaceutical and medical device innovators, we’ve been closely watching one development over the past year: the FDA’s long-awaited transition from the 1996 Quality System Regulation (QSR) to the 2024 Quality Management System Regulation (QMSR).

This shift – set to take effect in 02 February 2026 – is one of the most significant updates to U.S. device quality regulations in decades. While the industry has been anticipating alignment with ISO 13485 for years, the final rule brings both clarity and new expectations that every device manufacturer must understand. Aligning edits are also being made to 21 CFR Part 4, the FDA’s regulation for combination products.

Here’s our take on what is changing, what is staying the same, and how your organization can evolve alongside the transition.

Why the FDA is Moving to QMSR

The FDA’s revised Part 820, titled Quality Management System Regulation (QMSR), incorporates ISO 13485:2016 by reference, aligning the United States (U.S.) requirements with the international consensus standard used by regulators worldwide.

This alignment is intended to:

Harmonize global regulatory expectations
Streamline compliance for companies operating globally
Modernize the U.S. quality system framework
Reduce burden and promote consistency internationally

QMSR may be viewed as a welcome simplification for manufacturers already certified to ISO 13485; however, there is a cautionary tale: ISO 13485 certification does not guarantee FDA compliance. In preparation for these changes brought by QMSR, we’ll highlight a few focus areas and reiterate some more engrained quality concepts.

What’s Changing

Framework
ISO 13485:2016 becomes the foundation of the FDA’s quality system requirements. Most of the existing QSR text will be removed or replaced with reference to this ISO standard. The learning curve will be significant for those companies not already ISO 13485-certified; however, even ISO-certified organizations can expect FDA-specific requirements to remain intact.
Updated Terminology and Structure
The FDA will align most terms and definitions to those presented in ISO 13485:2016. For example, “Medical Device File” used in ISO 13485:2016 encompasses all device documentation in FDA-centric terms, such as Device Master Record (DMR), Design History File (DHF), and Device History Record (DHR). Keep hierarchy in mind, though, as the terms within the FD&C Act (Section 201) will reign. Definitions of ISO 13485:2016 terms that are superseded by the FDA (e.g., device, labeling) or additional terms that are not defined in ISO 13485:2016 (e.g., component, HCT/P) are contained in 21 CFR 820.3.
Risk Management
In the QSR, risk was implied and indirectly tied to design controls. In ISO 13485:2016, use of risk principles continues to be essential. Risk will become broadened and engrained in even more programs and elements across the QMS, with expectations to use risk-based thinking in programs like change management, corrective and preventative actions (CAPA), and supplier and purchasing controls.
Inspection Program
We expect changes to the FDA inspection program, as the agency has confirmed it will withdraw the current Quality System Inspection Technique (QSIT) on 02 February 2026, and replace it with a new inspection process aligned to QMSR. The new program will be available in a revised version of the Compliance Program (CP), Inspection of Medical Device Manufacturers (7382.845). We are waiting for this publication to become available on the FDA CDRH Compliance Program site no later than 02 February 2026.
Internal Records: Protection from Inspection?
Certain types of documents formerly exempt from FDA inspection in the QSR (§ 820.180(c)) are no longer maintained in the QMSR. This means that the FDA will have the authority and intention to inspect records related to management review, quality audits, and supplier audit documentation. According to the FDA, as manufacturers have been routinely providing these documents to other regulators, this change should not be an additional burden.

What’s Staying the Same

Design Controls
Design controls remain a cornerstone of FDA expectations. FDA continues to emphasize traceability, integration of risk management principles across the QMS, and documentation of product development.
Expectations for Packaging and Labeling Controls
ISO 13485 includes general labeling requirements, but FDA enforces detailed controls, including aspects such as label integrity, inspection, prevention of mix-ups, and U.S.-specific contents (e.g., UDI, warnings). Look to the new text covered in 21 CFR 820.45.
Recordkeeping Requirements and Product Complaints
FDA expectations exceed ISO 13485, particularly with respect to complaint files, MDR-related documentation (Part 803), correction and removal records (Part 806), and traceability records for certain device classes. These FDA requirements will remain enforced to ensure compliance with U.S. recordkeeping regulations. With regard to product complaint files, look to the more prescriptive text in amended section, 21 CFR 820.35.
Inspection Requirements
The FDA will continue to perform inspections to evaluate compliance with the requirements of its regulations. While ISO 13485 certification may help demonstrate a well-established quality system and reduce inspection burdens internationally, it does not replace FDA inspections or ensure FDA compliance.

How to Prepare and How Kymanox Can Help

We are already guiding our clients through the transition. Here’s what we recommend:

Achieve Understanding
Review the final QMSR rule and how it incorporates ISO 13485:2016. For combination product manufacturers, conforming edits are being made to 21 CFR Part 4.
Conduct a QMSR Gap Assessment
Even ISO-certified companies will have gaps, especially around FDA-specific expectations.
Update SOPs and Training to Strengthen Risk and Design Documentation
Remediate gaps from the assessment. Ensure risk and design documentation aligns with FDA expectations as scrutiny in these areas will remain high.
Prepare for QMSR-Aligned Inspections
Ensure your inspection readiness program reflects the new regulatory structure. Adapt your approach based on available information from FDA on the inspection methodology (e.g., QSIT-style thinking) adapted for QMSR.

Whether you need a quality system overhaul or targeted support, we’re ready to partner with you.

Check our our key takeaways from the recent FDA Townhall on QMSR

Read Key Takeaways

Preparing for QMSR inspections or navigating post-effective-date expectations?

Speak to Our Experts

Meet Global Quality Expectations

Kymanox helps organizations operationalize QMSR across the product lifecycle, connecting leadership, systems, and execution into a single, defensible quality framework.

+25000

Complaints Handled

+15000

SOPs Authored or Revised

+100

QMS Enhanced

+10

PAI or Mock Inspection Support

About Kymanox

Service Offerings

Business Models

Expertise You Can Trust

FDA QMSR Alignment to ISO 13485: Key Changes Ahead

SYNOPSIS

Why the FDA is Moving to QMSR

What’s Changing

Framework

Updated Terminology and Structure

Risk Management

Inspection Program

Internal Records: Protection from Inspection?

What’s Staying the Same

Design Controls

Expectations for Packaging and Labeling Controls

Recordkeeping Requirements and Product Complaints

Inspection Requirements

How to Prepare and How Kymanox Can Help

Achieve Understanding

Conduct a QMSR Gap Assessment

Update SOPs and Training to Strengthen Risk and Design Documentation

Prepare for QMSR-Aligned Inspections

Speak to Our Experts

Meet Global Quality Expectations

Stay Connected with our Thought Leadership

Thought Leadership

Events

Podcasts

Case Studies

How to Build a Scalable QMS from Clinic to Commercial